1.	Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Phase: Phase IV Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000454401, GERCOR-TAUROX, SANOFI-GERCOR-TAUROX, EU-20573, NCT00274885
2.	The Impact of Preoperative Oral Glutamine Intake on the Immunocompetence and Outcomes of Malnourished Patients Undergoing Major Abdominal Surgery Due to Malignancies Phase: Phase IV Type: Supportive care Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 170/11, NCT01552291
3.	Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced Neuroendocrine Tumors Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001K24133E1, NCT01595009
4.	Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Phase: Phase IV Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CSOM230B2412, NCT01794793
5.	Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 06-2247, NCT00442533
6.	Efficacy of an Oral Formula in Prevention of Anti-cancer Therapy Side Effects Phase: Phase III Type: Supportive care Status: Active Age: Over 18 Sponsor: Other Protocol IDs: 06.23.CLI, NCT00455247
7.	Study Comparing Isolated Pelvic Perfusion With TNF-a 0.3 mg and Melphalan 1.5 mg/kg Versus Standard Treatment in Patients With Non Resectable, Recurrent Gynaecologic or Digestive Pelvic Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 to 76 Sponsor: Other Protocol IDs: PIP2, CSET 1443, NCT00949039
8.	An Intervention to Improve Outcomes in Patients With Advanced Cancer Phase: Phase III Type: Educational/Counseling/Training, Supportive care Status: Active Age: 21 and over Sponsor: Other Protocol IDs: 0909005722, R01NR011872, NCT01272024
9.	Managing Cancer and Living Meaningfully (CALM): A Study to Evaluate the Effectiveness of a Psychological Intervention for Cancer Patients Phase: Phase III Type: Educational/Counseling/Training, Supportive care Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UHN REB 09-0855-C, CIHR, NCT01506492
10.	Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001T2302, 2011-002887-26, NCT01524783
11.	A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AAA-III-01, 2011-005049-11, NCT01578239
12.	TELESTAR (Telotristat Etiprate for Somatostatin Analogue Refractory Carcinoid Syndrome) Phase: Phase III Type: Supportive care Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: LX1606.1-301-CS, LX1606.301, NCT01677910
13.	Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors Phase: Phase III Type: Treatment Status: Approved-not yet active Age: 18 to 80 Sponsor: Other Protocol IDs: LOTUS, 2011-006097-76, NCT01755182
14.	Prevention of Oxaliplatin-induced Neuropathic Pain by a Specific Diet Phase: Phase III Type: Supportive care, Treatment Status: Approved-not yet active Age: 18 to 70 Sponsor: Other Protocol IDs: CHU-0137, 2011-A00911-40, NCT01775449
15.	Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer Phase: Phase III Type: Supportive care, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: 12-X387, NCT01790035
16.	Peritumoral Injection of Immature Dendritic Cells to Irradiated Skin Metastases of Solid Tumors Phase: Phase II, Phase I Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: immatureDC- HMO-CTIL, NCT00278018
17.	Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers Phase: Phase II, Phase I Type: Tissue collection/Repository Status: Active Age: Not specified Sponsor: Other Protocol IDs: 93-102, NCT00579163
18.	A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma Phase: Phase II, Phase I Type: Diagnostic Status: Active Age: 16 and over Sponsor: Other Protocol IDs: SP-24513/DX-FLT-002, NCT01065805
19.	A Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BBI608-201, NCT01325441
20.	Cell Therapy of Cancer With Allogeneic Blood Lymphocytes Activated With Recombinant Interleukin-2 (rIL-2) for Metastatic Solid Tumors Phase: Phase II Type: Treatment Status: Active Age: Under 70 Sponsor: Other Protocol IDs: 271296-HMO-CTIL, NCT00149006
21.	Pazopanib in Treating Patients With Advanced Neuroendocrine Cancer Phase: Phase II Type: Treatment Status: Active Age: 21 and over Sponsor: NCI Protocol IDs: NCI-2009-00201, MDACC 2006-0077, N01CM62202, 2006-0077, MDA-2006-0077, 7650, NCT00454363
22.	Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CRCA-CCTC-NET-01, EUDRACT-2004-005202-71, EU-207102, ISRCTN35124268, NCT00602082
23.	External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: IOSI-RO0402, RO0402, NCT00637637
24.	RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001CDE16, NCT00688623
25.	Study of Advanced Bulky Malignancies With Spatially Fractioned Radiation Therapy Phase: Phase II Type: Supportive care, Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: GRID, NCT00765570